Market Overview

Principia Confirms Human CNS Exposure and Good Tolerability of Oral BTK Inhibitor PRN2246

Share:

PRN2246 achieved full peripheral BTK occupancy at clinically relevant
dose levels studied

PRN2246 cerebral spinal fluid exposure was confirmed

Principia has achieved milestones of $15 million from collaboration with
Sanofi

Principia Biopharma Inc. today announced that dosing has been completed
for all participants in a Phase 1 clinical trial of PRN2246, a Bruton's
tyrosine kinase (BTK) inhibitor designed to cross the human blood-brain
barrier.

The double blind, placebo controlled, single and multiple ascending dose
trial is evaluating the pharmacokinetics, BTK receptor occupancy, safety
and tolerability of PRN2246 given orally to over 70 healthy volunteers.
PRN2246 has been well-tolerated in the study, and achieved high and
sustained peripheral BTK occupancy at clinically relevant dose levels
studied. Importantly, in a dedicated arm of the trial, exposure of
PRN2246 was confirmed in cerebral spinal fluid (CSF), highlighting the
potential for PRN2246 to impact B-cell driven inflammation in both the
periphery and central nervous system (CNS).

Upon Principia's completion of early development work, Sanofi plans to
develop this experimental oral therapy for the treatment of multiple
sclerosis (MS) and, potentially, other CNS diseases that are driven by
autoantibodies and inflammation. Potential for direct activity in the
CNS may allow targeting of disease mechanisms that are normally shielded
by the blood-brain barrier.

"Confirmation that PRN2246 crosses the blood-brain barrier in humans and
achieves therapeutic levels in the CSF is an important milestone for
this program and our collaboration with Sanofi," said Martin Babler,
Chief Executive Officer of Principia Biopharma. "We now look forward to
evaluating the potential additional benefit of modulating B-cells
directly in both the periphery and the CNS in MS patients."

About Principia Biopharma

Principia Biopharma Inc., a private, clinical-stage biopharmaceutical
company, has created a revolutionary new way to design and develop oral
small molecule therapies that are more potent, selective, durable and
safer than currently available drugs. The Company has utilized its
proprietary Tailored Covalency® technology to develop a portfolio of
drug candidates that exhibit antibody-like specificity to benefit
patients with autoimmune and inflammatory diseases and cancer. PRN1008,
a reversible covalent BTK inhibitor, is currently being evaluated in a
Phase 2 clinical trial in patients with pemphigus, an orphan autoimmune
disease, and in a Phase 2 clinical trial in patients with immune
thrombocytopenic purpura, an orphan hematological disease. PRN1371, a
covalent FGFR1-4 inhibitor, is currently being evaluated in a Phase 1
clinical trial in cancer patients with various solid tumors. PRN2246, a
low dose covalent BTK inhibitor which crosses the blood-brain barrier,
recently has completed dosing in a Phase 1 clinical trial in healthy
volunteers. For more information, please visit the Company's website at www.principiabio.com.

View Comments and Join the Discussion!